AviadoBio
Generated by Meeveem AI
"Developing precision gene therapies to delay or halt neurodegenerative disease progression"
London
•51 - 250 Employees
•Biotechnology
About AviadoBio
AviadoBio develops gene therapies for neurodegenerative diseases including frontotemporal dementia, retinitis pigmentosa, amyotrophic lateral sclerosis, and Alzheimer's disease. The company uses a neuroanatomy-led approach to overcome delivery challenges that have limited gene therapy effectiveness across the brain, spinal cord, and retina. Their proprietary vMiX platform enables one-time RNA silencing of disease-causing gene targets. Founded on research from King's College London and the UK Dementia Research Institute, AviadoBio translates scientific advances into medicines for patients who currently have few or no treatment options.
65
Team Members
2019
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where gene therapy effectively delays or halts neurodegenerative disease, giving patients renewed hope and additional years of cognitive and physical function.
Our Mission
At AviadoBio, our mission is to translate groundbreaking science and precision delivery into life-changing medicines for people living with neurodegenerative disorders.